|
|
|
|
|||||
|
|
|
New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.
Novo Nordisk stock lost 40% of its value in 2025.
The stock is already trading up 22% in 2026.
2025 was a miserable year to own Novo Nordisk (NYSE: NVO) stock.
Shares of the Danish pharmaceuticals giant and inventor of Wegovy and Ozempic crashed 40% last year as the company steadily lost market share to rivals such as Eli Lilly (NYSE: LLY), which has competing Mounjaro and Zepbound drugs, and Novo Nordisk's earnings fell in tandem. Novo Nordisk earned $6.53 in the first quarter of the year. By the third quarter, earnings had shrunk nearly 30% to just $4.50 per share.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
But does a 30% decline in profitability justify a 40% decline in stock price?
Perhaps not.
2026 started with a bang for Novo Nordisk stock. It almost seems like investors completed their 2025 tax-loss harvesting in December and were just waiting for the calendar to flip to 2026 to resume buying. Shares of the Ozempic maker jumped 3% on the first day of trading of the new year -- and they haven't looked back since. As of Thursday's close, the stock is already up 22% year to date.
Is there anything more behind this rally, though, than mere hope that this time will be different?
There may be. Already on Friday, data shows that prescriptions for an oral version of Novo Nordisk's Wegovy drug hit 18,000 in its second week on the market. That dwarfs the 8,000 prescriptions issued for Lilly's injectable Zepbound drug, and suggests that demand for GLP-1 medications in a convenient pill form might eclipse demand for any competing drugs that come only with a needle attached.
This news helped lift Novo Nordisk stock another percentage point or two by midday Friday.
With Novo Nordisk trading at only a 17 price-to-earnings ratio and demand for the pills already surging, I predict Novo Nordisk stock will continue to rebound in 2026.
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $462,174!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,143,099!*
Now, it’s worth noting Stock Advisor’s total average return is 946% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of January 27, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
| 3 hours | |
| 3 hours | |
| 5 hours | |
| 5 hours | |
| 7 hours | |
| 7 hours | |
| 7 hours | |
| 8 hours | |
| 8 hours | |
| 9 hours | |
| 9 hours | |
| 11 hours | |
| 12 hours | |
| 14 hours | |
| Jan-26 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite